ISSUE 11/2025

# BDMAI BULLETIN


## From the Desk of President

Dear Friends,

Greetings from BDMAI!

I hope you all had a great time during the recently concluded CPhI Worldwide 2025, renewing old associations and entering into new partnerships. Events like these remind us of India's growing prominence in the global pharmaceutical supply chain and the need to constantly evolve to stay ahead.

I would like to share my views on an important topic. Our industry stands at the threshold of a technological revolution — one driven by Artificial Intelligence (AI) and data-driven decision-making. Around the world, AI is transforming every aspect of healthcare and manufacturing, and the Bulk Drug (API) sector is no exception.

AI offers immense potential to optimize our processes — from R&D and process development to yield improvement, quality control, predictive maintenance, and supply chain management. However, there still exists a myth that AI is relevant only for large-scale or high-tech industries. In reality, even MSMEs can benefit significantly from AI-based tools that improve process efficiency, reduce costs, and enhance compliance with GMP and environmental standards.

The need of the hour is to build awareness, develop digital readiness, and encourage practical adoption of AI solutions tailored for our industry's unique challenges. The future competitiveness of Indian Bulk Drug manufacturing will depend not only on chemistry and engineering excellence but also on our ability to harness digital and intelligent technologies effectively.

Recognizing this importance, BDMAI is planning to organize a one-day seminar on "AI & Digitalization in Bulk Drug

Manufacturing" to create awareness among industry professionals and explore real-world applications and success stories. Schedule of the Seminar will be shared with members soon. We look forward to the participation of our members, technology providers, and experts in making this initiative a meaningful step toward a smarter, more efficient, and globally competitive Indian API industry.

With best regards

Ch A P Rameswara Rao
National President

## In this Bulletin you can expect

# Investments

## Kailera nets $600m to power Phase III launch of obesity drug

Weight loss treatment-focused biotechs are bucking the wider downturn in early-stage investments. Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another financing goal, raising $600m to fund a Phase III trial of its promising weight loss drug. Kailera, one of the industry's most closely watched private biotechs, secured the funds as part of a Series B financing round led by new investor Bain Capital. The US firm is hoping to seize a share of the lucrative cardiometabolic market with its lead candidate KAI-9531, an injectable dual GLP-1/GIP receptor agonist.

***Pharmaceutical Technologies 14.10.2025***

## Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn

Bristol Myers Squibb (BMS) has added to its cell therapy portfolio, paying $1.5 billion for the US biotech Orbital Therapeutics. At the heart of the deal is the Cambridge, Massachusetts-based biotech company's investigational *in vivo* chimeric antigen receptor (CAR) T-cell therapy OTX-201, which targets autoimmune diseases. Robert Plenge, Chief Research Officer at BMS, said: "*In vivo* CAR T represents a novel treatment approach that could redefine how we treat autoimmune diseases.

***European Pharmaceutical Review 15.10.2025***

## AstraZeneca doubles Lokelma production at its Texas facility

The pharma company invested $445m to expand its Coppell site. AstraZeneca has doubled production capacity for its hyperkalaemia treatment Lokelma (sodium zirconium cyclosilicate) after completing a $445 million expansion of its manufacturing facility at Coppell in Texas. The pharma company added a new 9,000 square foot building and two novel manufacturing lines at the site, which is Lokelma's sole global manufacturing facility. Available as powder sachets, Lokelma was first approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) in 2018

***European Pharmaceutical Review 16.10.2025***

## Adcytherix gains $122m to propel ADC development

Adcytherix has set a target to file for an IND and clinical trial applications in Canada, the UK, and the EU by the end of 2025. France-based Adcytherix has completed a Series A funding round, raising €105m ($122m) earmarked for expediting the antibody-drug conjugate (ADC) pipeline with a focus on new payloads. The funds will be used to progress the company's primary candidate, ADCX-020, into clinics.

***Pharmaceutical Technologies 18.10.2025***

## Tubulis Raises €308M to Advance Antibody-Drug Conjugate Pipeline

Tubulis, a German biotech company specializing in next-generation antibody-drug conjugates (ADCs), has secured €308 million (USD 361 million) in a major Series C financing round aimed at accelerating the clinical development of its lead oncology programs. The round was led by Venrock Healthcare Capital Partners, with participation from new investors Wellington Management and Ascenta Capital. Existing backers including Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, and others also joined the round.

***Pharma Journallist 17.10.2025***

## ENA Respiratory secures US$22.4m to advance nasal spray therapy

Funding to support phase 2 trial of INNA-051 aimed at preventing viral respiratory infections - ENA Respiratory has raised US$22.4m (AU$34m) in Series B financing to support the phase 2 clinical development of its nasal spray therapy, INNA-051. The Melbourne-based pharmaceutical company welcomed new investment from the Gates Foundation and Flu Lab, alongside continued backing from Brandon Capital, Uniseed and Stoic Venture Capital.

***Pharma Times 22.10.2025***

# New Drug Developments

### AbbVie unveils new data on solid tumour therapies

**Phase 1 and phase 2 results highlight promise of ADCs for hard-to-treat cancers**

AbbVie has announced new clinical data from its antibody-drug conjugate (ADC) platform, reinforcing its commitment to advancing targeted therapies for solid tumours. The data will be presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, taking place from 17 to 21 October. The company's investigational ADCs, including telisotuzumab adizutecan (Temab-A) and ABBV-706, demonstrated encouraging results across pancreatic, colorectal and other solid tumour types. AbbVie also shared updates on Emrelis (telisotuzumab vedotin), which is already approved for certain indications.

***Pharma Times 14.10.2025***

## FDA grants fast Track status to Enterome's EO2463 for follicular lymphoma

**Designation supports phase 3 launch in watch-and-wait patients in 2026**

Enterome has received fast track designation from the US Food and Drug Administration for its lead OncoMimics immunotherapy EO2463, targeting follicular lymphoma in the low tumour burden 'watch-and-wait' setting. The designation highlights EO2463's potential as a first-in-class monotherapy for patients who typically do not receive treatment unless symptoms emerge.

***Pharma Times 14.10. 2025***

## NIHR invests £157 million in research partnerships to transform healthcare

**Applied Research Collaborations to drive innovation and tackle inequalities across England**

The National Institute for Health and Care Research (NIHR) has announced a £157 million investment over 5 years to support 10 new Applied Research Collaborations (ARCs) across England, beginning in April 2026. The ARCs will help deliver the ambitions of the NHS 10 Year Plan, the Life Sciences Sector Plan and the Government's Health and Growth Missions. These collaborative partnerships between universities, NHS trusts, local authorities, Health Innovation Networks, Integrated Care Boards and the voluntary sector will focus on applied research to address pressing health and social care challenges

***Pharma Times 15.10.2025***

## Johnson & Johnson's (J&J's) bispecific Rybrevant (amivantamab) could provide an effective, novel option for patients with head and neck squamous cell cancer (HNSCC)

This follows the positive results of the Phase Ib/II OrigAMI-4 study (NCT06385080), which saw the subcutaneous therapy trigger an objective response rate (ORR) of 45%. Of these patients, one achieved a complete response (CR), while 12 achieved partial responses (PR). Stable disease was experienced by 15 patients in the Rybrevant monotherapy arm, meaning that 82% of patients given the drug experienced a clinical benefit

***Pharmaceutical Technologies 20.10.2025***

## Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm, a leading global contract development and manufacturing organisation (CDMO), today announced the successful cGMP manufacture of PnuBioVax®, a new protein-based vaccine against pneumococcal disease developed by ImmunoBiology Ltd (ImmBio) and the Infection Innovation Consortium (iiCON). This milestone has enabled the start of Phase 2 clinical trials in Malawi, the largest human challenge trial ever conducted in the country.

***World Pharma 19.10.2025***

## Astellas' treatment shows promise for menopause symptoms

There have been encouraging preliminary findings from Astellas Pharma's ongoing phase 4 OPTION-VMS observational study, showing that fezolinetant significantly improves symptoms of vasomotor symptoms (VMS) associated with menopause. Involving over 900 women aged 40–75 with confirmed menopausal VMS, the study demonstrated statistically significant improvements in VMS bother, sleep quality and work productivity at weeks 4, 8 and 12. The study also reported statistically significant improvements in both subjective and objective sleep outcomes, including sleep efficiency and wakefulness after sleep onset. Improvements were measured using PROMIS SD SF 8b and actigraphy endpoints.

***PF Media 30.10.2025***

# Drug Approvals

## FDA approves Glaukos' Epioxa as incision-free corneal disease treatment

The approval marks the first pharma-based therapy option that does not require corneal removal. The US Food and Drug Administration (FDA) has approved Glaukos Corporation's Epioxa, offering patients living with a rare corneal disease a treatment option that does not require incisions. Epioxa, which contains an active component from a bio-activated formulation of riboflavin, will be available to patients with keratoconus, an eye condition in which the cornea becomes gradually thinner, ultimately leading to vision loss. Glaukos intends for the therapy to be commercially available in Q1 2026.

**Pharmaceutical Technologies 20.10.2025**

# Mergers & Acquisitions

## Ipsen strikes €1bn deal to acquire French biotech ImCheck Therapeutics

The move will boost its oncology pipeline, adding a potential first-in-class anti-BTN3A monoclonal antibody for acute myeloid leukaemia. Ipsen is set to acquire French biotech ImCheck Therapeutics in a move that will strengthen its oncology pipeline by adding rights to a potential first-in-class anti-BTN3A monoclonal antibody. ImCheck's lead asset ICT01 is currently being evaluated in an ongoing phase I/II EVICTION trial in first line acute myeloid leukaemia (AML) patients who are ineligible for intensive chemotherapy. The biologic's unique mechanism of action modulates both innate and adaptive immunity and recent clinical data suggests that in combination with Ven-Aza (venetoclax and azacitidine) ICT01 has potential as a novel immunotherapy for AML

**European pharmaceutical Review 23.10.2025**

# Regulations

## FDA Releases Biosimilar Guidance Pushing to Streamline Development

- The FDA's updated guidance prioritizes comparative analytical assessments over comparative efficacy studies for biosimilar development, aiming to streamline the approval process.
- Conditions for waiving CES include high purification, well-characterized analytical tests, and feasible pharmacokinetic studies, enhancing specificity and sensitivity.
- The FDA emphasizes personalized approaches for biosimilar development, ensuring safety and efficacy while reducing bureaucratic delays.
- The new approach is expected to benefit patients, providers, and manufacturers by lowering costs and accelerating market access for biosimilars.

***Drug Topics 1.11.2025***

## ASSOCIATION ACTIVITIES

### Representations:

Following Representations were made during October 2025:

**APPCB, Andhra Pradesh:** Requested for directing the concerned authorities to implement the revised COD limit of up to 500 mg/l is limits as per the MoEF & CC notification No. 3864(E) dated 9th September 2024. Click **HERE** to see the detailed representation.

**GST Council**: Represented to GST Council requesting to maintain the status quo on GST rates for APIs and Intermediates. Click **HERE** to see the detailed representation

**APIIC:** Representation to Dr. N. Yuvaraj, IAS, Secretary to Government, Industries and Commerce, Dept. Govt. of Andhra Pradesh requesting for allotment of Land to MSME Manufacturers in Nakkapalli Bulk Drug Park. Please click **HERE** for a detailed representation

### CIRCULARS:

7TH October 2025: About Pharma Bulk Drug Manufacturing Summit on 15.10.2025, where our National President was the Chief Guest for this Summit.

27th of October 2025: Informing members about SIDBI offering Term / Soft Loans under Arogya Scheme for Pharmaceutical Industry

**31st of October 2025:** Informing the members about 12th India Pharma Awards by CPhHi India and inviting members to participate in the prestigious 12th India Pharma Awards 2025

**3rd of November 2025** Informing the members about Hon'ble Chief Minister of Punjab's visit to Hyderabad on 11.1.2025

# Events:

## Recruitment Drive:

In association with Telangana Council for Higher Education and Palamur University, BDMAI organized a Recruitment Drive at the University campus of Palamur University on 11th October



2025. Eight of member companies participated in the Recruitment Drive. University officials made extensive arrangements for the drive.

## Pharma Summit on Bulk Drug Manufacturing


BDMAI actively supported Pharma Summit on Bulk Drug Manufacturing which was organized on 15th October 2025 by ICEXPO at Hotel Radison Blue, Hyderabad. The Summit was well attended by our members. National President of BDAMAI Sri Ch A P Rameswar Rao was the Chief Guest of the event.

## Process Safety in Pharma Industry:

BDMAI supported the one-day seminar on **Corrosion Risk Management and Process Safety in Pharma and Chemical Industry"** on **October 15, 2025** at **Sheraton Hyderabad Hotel, Hyderabad**, organized by Indian Pharma Post (IPP), in association with Alleima. The event was well organized and presented useful information to the audience. Sri Ch A P Raameswara Rao, National President of BDMAI was the Guest of Honor of the event.

## Important Notifications:

### New Drug Approvals:

DCGI issued a Public Notice inviting comment from stakeholders to ensure a level playing field in new drug approval. Please click HERE to see the Public Notice issued by CDSCO on this subject.

### Green Belt requirements

Impact Assessment Division of MoEF & CC issued an Office Memorandum specifying the Green Belt Requirements for various sectors within Industrial area and outside Industrial Areas. Please click **HERE** for a detailed OM.

### Implementation of Revised Schedule:

Enforcement Division of CDSCO issued an internal circular on 7th November 2025 directing the State Drug Controllers to inspect the manufacturing units, who have applied for extension of time for implementing Schedule M till 31.12.2025. Please click **HERE** to see the internal circular.

# Green Manufacturing: Reducing Carbon Footprint in the Pharma Sector

## Introduction

The pharmaceutical industry is highly energy and water-intensive, with cooling systems among its largest consumers. These systems are vital for process cooling, HVAC in cleanrooms and condenser cooling for chillers. As the sector transitions towards greener manufacturing, Thermax offers advanced closed-loop and hybrid cooling solutions that enable pharmaceutical facilities to reduce carbon footprint, conserve water and ensure process hygiene - all while improving reliability and compliance.

## Cooling and its role in Carbon Reduction

Cooling infrastructure directly influences a plant's carbon footprint through electricity and water consumption. Conventional open-loop cooling towers often suffer from fouling, scaling and microbial growth, reducing system efficiency and increasing energy use.
By replacing these with Thermax's closed-loop or hybrid closed-loop systems, pharma manufacturers can achieve

- Higher energy efficiency through clean heat transfer surfaces
- Reduced water consumption by up to 95%
- Lower chemical use and blowdown losses
- Improved reliability with consistent performance and reduced maintenance

These efficiencies translate into measurable reductions in both Scope 2 (electricity-related) and embodied emissions, aligning with sustainability and ESG goals.

## Where are Cooling Solutions used in Pharma?

Thermax's cooling solutions cater to every critical application within pharma operations.

1. Chiller Condenser Cooling – for water-cooled chillers supporting cleanrooms and controlled environments
2. Direct Process Cooling – for reactors, fermenters, distillation condensers and lyophilizers
3. Utility Equipment Cooling – for compressors and vacuum pumps
4. Ancillary Systems – for laboratory equipment and pre-cooling in CIP systems

Each of these applications demand reliability, temperature precision and contamination-free cooling - all of which are inherent advantages of closed-loop designs.

## Challenges with Conventional Open-Loop Cooling

Traditional open-loop cooling towers expose circulating water to the atmosphere, leading to,

- Microbial growth and biofilm risks that complicate compliance in sterile environments
- High evaporation and blowdown losses
- Fouling and scaling that increase energy consumption
- Heavy chemical dependence for water treatment
- Seasonal variations affecting process stability

**Thermax Closed-Loop Cooling Systems: Smart, Sustainable, and Reliable:** Thermax has pioneered sustainable cooling technologies designed for long-term performance and hygiene in pharma operations.

**1.Closed-Loop Cooling Towers:**

Ensure clean, sealed circuits where process water never contacts ambient air. This maintains efficiency, reduces scaling and eliminates the need for separate primary and secondary pumping systems.

**2. Hybrid Closed-Loop Cooling Towers:**

Deliver up to 50% water savings by combining evaporative and dry cooling. They intelligently switch between modes based on ambient conditions to balance efficiency and conservation.

**3. Adiabatic Cooling Towers:**

Offer up to 95% water savings by using pre-cooled air instead of direct evaporation - ideal for regions facing water scarcity. Together, these systems help pharma manufacturers enhance productivity while meeting their sustainability and compliance goals.

### How Thermax Systems Cut Carbon Emissions

1. Energy Efficiency: Clean heat exchangers ensure chillers operate at optimal COP levels
2. No Additional Pumps Required: Closed design eliminates intermediate exchangers and pump sets, saving power
3. Heat Recovery Integration: Enables recovery of waste heat for reuse in process heating
4. Reduced Water & Chemical Use: Cuts embodied carbon in treatment and procurement
5. Enhanced Reliability: Reduced downtime and smoother operation ensure long-term energy savings

Even a modest 3% gain in chiller efficiency can save around 40,000 kWh per year, reducing more than 30 tonnes of $CO_2$ - proving that incremental improvements lead to significant sustainability gains.

## Expanding Efficiency: Heat Pump Technology for Pharma Hot Water

Thermax extends its decarbonization expertise beyond cooling with industrial heat pumps, offering a clean and efficient alternative to fossil-fuel-based boilers for process and utility hot water up to 120°C.

## How Thermax Heat Pumps Work

They capture waste heat from chillers or process water and upgrade it via vapor compression or absorption cycles - delivering 3-5 times the heat energy for every unit of electricity consumed.

## Types of Thermax Heat Pumps

- Absorption Heat Pumps: Driven by thermal energy (steam, hot water, or gas)
- Electrical Heat Pumps: Powered by electricity, ideal for renewable integration
- Hybrid Systems: Combine both technologies for high flexibility

**Applications in Pharma Industry**

- Process Hot Water: For reactor jackets, fermenters, and sterilization systems (70–95°C)
- Utility Hot Water: For HVAC coils and domestic use (60–70°C)
- Boiler Feedwater Preheating: Reduces boiler fuel consumption (up to 110°C)
- Space Heating & Dehumidification: Ideal for controlled environments in cold regions

## Sustainability & Cost Advantages

Thermax's heat pumps directly contribute to decarbonization by:

- Replacing fossil fuel-based boilers
- Cutting $CO_2$ emissions through electrification and waste heat recovery
- Achieving COP values of 3-5, ensuring substantial energy savings
- Reducing chemical and water use tied to steam generation
- Supporting ESG and net-zero reporting goals

They also offer modular scalability, safety and integration flexibility - making them ideal for both greenfield and retrofit pharma projects.

## Conclusion

For the pharmaceutical industry, Thermax provides a clear pathway toward green manufacturing. By adopting closed-loop cooling systems and industrial heat pumps, companies can simultaneously enhance operational reliability, reduce carbon emissions and conserve vital resources.

These solutions embody Thermax's vision of "Trusted Partner In Energy Transition," helping pharma manufacturers move closer to net-zero while maintaining the precision and purity their processes demand. In every drop saved and every unit of energy optimized, Thermax empowers the pharma sector to make sustainability a core part of performance.

# Quality Culture, Quality Metrics, Quality Management Maturity- Pillars of Integrity

***Dr. Ajay Babu Pazhayattil, President, cGMPWorld***

In the current period of increasing regulatory scrutiny and complex global supply chains, data integrity (DI) and quality culture have emerged as foundational pillars of pharmaceutical quality management. In spite of the longstanding regulatory emphasis, persistent gaps in DI practices continue to challenge industry compliance both in India and globally. Empirical studies, including FDA funded research, have demonstrated that measurable improvements in quality culture directly enhance data reliability and organizational commitment to continuous improvement. The long favoured ignorance plea tactic has been historically ineffective in defending DI failures. Regulatory agencies and manufacturers are now aligned on advancing Quality Management Maturity (QMM) as a mechanism to strengthen sustainable compliance.

Reliability of data is directly linked to the existence of a strong quality culture within an organization. The FDA funded University of St. Gallen research [1] supports this and concludes that the introduction of metrics can improve organizational commitment to a quality culture. FDA warning letters (WL) review shows that DI remains one of the most frequent and critical areas of non compliance [2]. Consciously infusing DI focused practices and regularly measuring its effectiveness can reduce DI regulatory risks and improve operational efficiency. This requires organizations to engage industry experts, adopt enabling technologies, and reinforce a mindset of integrity.

*Figure 1: Evolution Timeline*


Quality metrics, as suggested by the US FDA [3], evaluate product and process performance across the product lifecycle. The metrics provide valuable insights into manufacturing consistency and are key to achieving Quality Management Maturity (QMM). They can help organizations maintain control over manufacturing processes, support continuous improvement, and enhance overall product quality and reliability. Compliance with current Good Manufacturing Practice (cGMP) ensures that products meet minimum safety and quality standards, but quality metrics go further, promoting sustainable compliance through continuous improvement. Within a robust

Pharmaceutical Quality System (PQS) [4], quality metrics enable data driven decisions that strengthen supply chain resilience, guide supplier oversight, and prevent disruptions. They serve as valuable tools for regulatory agencies to better understand manufacturing performance and identify early signals of potential quality or supply disruptions. The FDA recognize quality metrics as central to advancing its risk-based regulatory oversight model.

*Figure 2: Quality Metric Framework*




Through its Quality Metrics Reporting Program, the FDA aimed to collect standardized data from manufacturing sites to quantify quality performance, integrate this information into its surveillance and risk-prioritization process, and use it to optimize inspection scheduling, reducing burdens for best performing sites. The agency's effort to establish this program has evolved through extensive collaboration with industry. Following early discussions and public consultations beginning in 2013, the FDA issued draft guidances in 2015 and 2016 outlining the structure of the Quality Metrics Reporting. Industry feedback led to a shift from a mandatory to a voluntary, phased approach, allowing iterative refinement for both regulator and manufacturers. Subsequent pilot programs in 2018, including the quality metrics site visit and feedback initiatives, helped the FDA gather real-world input on metric selection and reporting feasibility. By 2022, the agency continued refining the framework based on lessons learned and stakeholder feedback. Ultimately, metrics and key performance indicators (KPIs) have become central to proactive, data-driven decision making, helping organizations prevent failures that could lead to revenue loss and supply disruptions. It is essential for bulk drug manufacturers to voluntarily adopt and track metrics such as Lot Acceptance Rates (LAR), Product Quality Compliant Rate (PQCR), invalidated Our-Of-Specification Rate (IOOSR) [5], as clients increasingly use these indicators to assess CMO site performance.

The Center for Drug Evaluation and Research (CDER) Quality Management Maturity (QMM) framework seeks to strengthen quality culture, recognize establishments with advanced quality systems, and identify growth opportunities for continual improvement. By promoting mature quality management practices, the initiative aims to reduce quality

related failures, enhance supply chain resilience, and ensure reliable supply. CDER white paper on QMM [6] emphasizes that strategic investments in quality management can deliver measurable returns for both manufacturers and public health. To advance this, the 2025 QMM Prototype Assessment Protocol Evaluation Program [7] invited establishments to participate in testing CDERs assessment tool for evaluating quality maturity. The QMM initiative builds on earlier findings, which linked drug shortages to the lack of incentives for manufacturers to exceed minimum regulatory standards.

An integrated approach with organizational awareness programs, strategic technology adoption, risk management, and portfolio reassessment is required to deliver and maintain maturity. For bulk drug manufacturers, the journey towards QMM begins with people integrity, starting from robust recruitment practices and leadership behaviour. Embedding a culture of integrity supported by quality metrics and maturity frameworks transforms compliance from a reactive necessity into a strategic advantage. Establishing such a foundation requires transparency, accountability, and personnel integrity, supported by data-driven and risk-based decision-making.

References:


1. *St.Gallen FDA Quality Metrics Research:* https://item.unisg.ch/divisions/production-management/focus/operational-excellence/quality-metrics-research/
2. *US FDA Warning Letters:* https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters
3. *US FDA Quality Metrics for Drug Manufacturing:* https://www.fda.gov/drugs/pharmaceutical-quality-resources/quality-metrics-drug-manufacturing
4. *ICH Guideline, Pharmaceutical Quality System (Q10):* https://database.ich.org/sites/default/files/Q10%20Guideline.pdf
5. US FDA Guidance for Industry, Submission of Quality Metrics Data: www.fda.gov/files/drugs/published/Submission-of-Quality-Metrics-Data-Guidance-for-Industry.pdf
6. *US FDA, Quality Management Initiatives in the Pharmaceutical Industry: An Economic Perspective:* www.fda.gov/media/187861/download?attachment
7. *US FDA, Voluntary Quality Management Maturity Prototype Assessment Protocol Evaluation Program:* https://www.federalregister.gov/documents/2025/04/23/2025-06968/voluntary-quality-management-maturity-prototype-assessment-protocol-evaluation-program

# Country-wise Exports of Bulk Drugs & Intermediates April-Sept 2025

Value in $ mn

| Country | April - Sep 2024 | April - Sep 2025 |
|---|---|---|
| Afghanistan | 0.77 | 0.92 |
| Albania | 0.10 | 0.04 |
| Algeria | 23.29 | 16.57 |
| Angola | 0.73 | 0.83 |
| Antigua | 0.00 | 0.00 |
| Argentina | 15.97 | 17.37 |
| Armenia | 0.03 | 0.06 |
| AUSTRALIA | 7.23 | 6.48 |
| Austria | 4.58 | 5.64 |
| Azerbaijan | 0.03 | 0.21 |
| Bahrain | 0.29 | 0.15 |
| Bangladesh | 89.71 | 71.67 |
| Barbados | 0.08 | 0.07 |
| Belarus | 1.85 | 1.72 |
| Belgium | 85.52 | 65.48 |
| Belize | 0.00 | 0.00 |
| Benin | 0.37 | 0.03 |
| Bhutan | 0.29 | 0.41 |
| Bolivia | 0.72 | 0.73 |
| Bosnia Herzegovina | 0.38 | 0.29 |
| Botswana | 0.00 | 0.02 |
| Brazil | 102.40 | 102.64 |
| British Virgin Islands | 0.00 | 0.00 |
| Brunei | 0.00 | 0.04 |
| Bulgaria | 2.91 | 3.39 |
| Burkina Faso | 0.01 | 0.01 |
| Burundi | 0.02 | 0.00 |
| Cambodia | 0.57 | 1.50 |
| Cameroon | 0.61 | 0.78 |
| Canada | 24.61 | 39.74 |
| Cape Verde Is | 0.00 | 0.01 |
| Cayman Islands | 0.00 | 0.00 |
| Central African Republic | 0.00 | 0.00 |
| Chad | 0.16 | 0.00 |
| Chile | 5.05 | 7.19 |
| CHINA | 87.11 | 87.90 |
| Colombia | 17.38 | 19.24 |
| Comoros | 0.00 | 0.00 |
| CONGO D REP | 5.80 | 6.44 |
| Congo P. Republic | 0.08 | 0.18 |
| Costa Rica | 1.53 | 4.15 |
| Cote D' Ivoire | 2.49 | 1.95 |
| Croatia | 9.46 | 21.17 |
| Cuba | 0.23 | 0.09 |

| | | |
|---|---|---|
| Cyprus | 7.74 | 5.75 |
| Czech Rep. | 4.41 | 5.46 |
| Denmark | 2.28 | 3.21 |
| Djibouti | 0.44 | 1.24 |
| Dominica | 0.01 | 0.00 |
| Dominican Republic | 1.70 | 2.13 |
| Ecuador | 1.23 | 2.18 |
| Egypt | 68.47 | 65.58 |
| El Salvador | 1.84 | 1.76 |
| Eritrea | 0.07 | 0.08 |
| Estonia | 1.05 | 0.16 |
| Ethiopia | 2.60 | 3.52 |
| Fiji | 0.05 | 0.06 |
| Finland | 1.90 | 1.36 |
| Fr Polynesia | 0.01 | 0.01 |
| France | 54.87 | 60.66 |
| Gabon | 0.01 | 0.08 |
| Gambia | 0.00 | 0.00 |
| Georgia | 0.18 | 0.41 |
| Germany | 59.00 | 70.17 |
| Ghana | 12.53 | 11.32 |
| Greece | 25.90 | 13.36 |
| Grenada | 0.02 | 0.00 |
| Guam | 0.03 | 0.01 |
| Guatemala | 3.40 | 3.88 |
| Guinea | 0.01 | 0.18 |
| Guinea Bissau | 0.00 | 0.00 |
| Guyana | 0.02 | 0.05 |
| Haiti | 0.02 | 0.03 |
| Honduras | 0.46 | 0.36 |
| Hong Kong | 4.98 | 3.77 |
| Hungary | 8.29 | 8.07 |
| Iceland | 1.65 | 2.54 |
| Indonesia | 55.75 | 51.25 |
| Iran | 4.94 | 3.59 |
| Iraq | 8.16 | 8.69 |
| Ireland | 25.34 | 33.23 |
| Israel | 8.04 | 9.21 |
| Italy | 65.23 | 50.68 |
| Jamaica | 0.09 | 0.13 |
| Japan | 55.54 | 58.69 |
| Jordan | 18.62 | 17.49 |
| Kazakhstan | 1.06 | 0.50 |
| Kenya | 24.80 | 27.55 |
| Korea Republic (South) | 67.52 | 52.87 |
| Kuwait | 0.68 | 1.09 |
| Kyrgyzstan | 0.94 | 3.48 |
| Laos | 0.55 | 1.47 |
| Latvia | 0.47 | 0.27 |
| Lebanon | 9.32 | 7.16 |

| | | |
|---|---|---|
| Liberia | 0.07 | 0.14 |
| Libya | 0.00 | 0.06 |
| Liechtenstein | 0.00 | 0.00 |
| Lithuania | 1.64 | 1.76 |
| Luxembourg | 0.00 | 0.00 |
| Macao | 0.22 | 0.01 |
| Macedonia | 5.55 | 4.85 |
| Madagascar | 0.17 | 0.18 |
| Malawi | 0.52 | 0.29 |
| Malaysia | 15.71 | 14.10 |
| Maldives | 0.00 | 0.00 |
| Mali | 0.03 | 0.01 |
| Malta | 3.88 | 6.97 |
| Mauritania | 0.00 | 0.00 |
| Mauritius | 0.09 | 0.07 |
| Mexico | 52.66 | 39.73 |
| Micronesia | 0.00 | 0.00 |
| Moldova | 0.14 | 0.17 |
| Mongolia | 0.01 | 0.00 |
| Morocco | 6.99 | 7.22 |
| Mozambique | 6.46 | 4.88 |
| Myanmar | 2.80 | 2.19 |
| Namibia | 0.02 | 0.00 |
| Nepal | 15.62 | 13.13 |
| Netherlands | 62.80 | 86.52 |
| Netherlands Antilles | 0.00 | 0.00 |
| New Zealand | 1.98 | 0.48 |
| Nicaragua | 0.53 | 0.52 |
| Niger | 0.01 | 0.02 |
| Nigeria | 24.13 | 25.47 |
| Norway | 0.56 | 4.56 |
| Oman | 3.82 | 5.65 |
| Pakistan | 29.90 | 14.47 |
| Palau | 0.00 | 0.00 |
| Panama Republic | 0.36 | 0.34 |
| Papua New Guinea | 0.02 | 0.00 |
| Paraguay | 2.24 | 6.23 |
| Peru | 4.69 | 4.15 |
| Philippines | 10.50 | 8.65 |
| POLAND | 21.35 | 26.99 |
| Portugal | 11.28 | 10.87 |
| Puerto Rico | 4.38 | 8.03 |
| Qatar | 0.13 | 0.20 |
| Romania | 7.28 | 7.10 |
| Russia | 61.44 | 52.02 |
| Rwanda | 0.01 | 0.08 |
| Saudi Arabia | 19.87 | 19.85 |
| Senegal | 0.55 | 1.40 |
| Serbia | 5.91 | 3.35 |
| Seychelles | 0.00 | 0.00 |

| | | |
|---|---|---|
| Sierra Leone | 0.13 | 0.25 |
| Singapore | 30.96 | 18.34 |
| Slovak Rep | 0.58 | 1.37 |
| Slovenia | 2.62 | 5.14 |
| Somalia | 0.04 | 0.02 |
| South Africa | 17.12 | 8.62 |
| South Sudan | 0.01 | 0.00 |
| Spain | 61.28 | 59.88 |
| Sri Lanka | 8.70 | 8.72 |
| St Kitt N A | 0.00 | 0.00 |
| St Lucia | 0.00 | 0.00 |
| Sudan | 0.02 | 0.46 |
| Suriname | 0.01 | 0.05 |
| Swaziland | 1.71 | 3.44 |
| SWEDEN | 0.06 | 2.46 |
| Switzerland | 54.12 | 24.18 |
| Syria | 0.87 | 1.28 |
| Taiwan | 16.24 | 19.03 |
| Tajikistan | 0.03 | 0.05 |
| Tanzania | 9.47 | 11.80 |
| Thailand | 29.44 | 34.26 |
| Timor-Leste | 0.00 | 0.00 |
| Togo | 2.60 | 1.75 |
| Trinidad and Tobago | 0.00 | 0.00 |
| Tunisia | 4.35 | 3.39 |
| Turkey | 56.84 | 64.35 |
| Turkmenistan | 0.01 | 0.60 |
| U S A | 188.99 | 260.69 |
| Uganda | 3.13 | 3.76 |
| Ukraine | 0.61 | 0.55 |
| United Arab Emirates | 67.32 | 50.75 |
| United Kingdom | 34.15 | 35.71 |
| UNSPECIFIED | 0.70 | 157.60 |
| Uruguay | 3.07 | 5.96 |
| Uzbekistan | 0.87 | 1.40 |
| Vanuatu | 0.00 | 0.00 |
| Venezuela | 0.92 | 1.77 |
| Vietnam Soc Rep | 47.51 | 41.33 |
| VIRGIN IS US | 0.00 | 0.01 |
| Yemen Republc | 1.82 | 1.24 |
| Zambia | 1.18 | 0.31 |
| Zimbabwe | 0.32 | 0.84 |
| **Grand Total** | 2138.67 | 2293.94 |

| HS code0-wise Exports of Bulk Drugs & Drug Intermediates April- | | | | | |
|---|---|---|---|---|---|
| | | | | | Value in $ Mn |
| **HS codes** | **Description** | **Sep-24** | **Sep 2025** | **2024-25** | **2025-26** |
| 17023010 | Glucose liquid | 3.258 | 3.178 | 26.221 | 26.025 |
| 17023020 | Glucose solid | 0.927 | 0.495 | 5.628 | 3.513 |
| 17023031 | Dextrose,solid | 1.452 | 0.730 | 8.302 | 9.201 |
| 17023039 | Dextrose other than solid | 0.003 | 0.023 | 0.211 | 0.194 |
| 17024039 | Dextrose other than solid | 0.001 | 0.003 | 0.079 | 0.050 |
| 29051410 | Ethambutol, ethambutol hcl | 1.313 | 0.471 | 4.362 | 2.502 |
| 29051420 | Salbutamol sulphate | 0.901 | 1.036 | 5.762 | 5.405 |
| 29054300 | Mannitol | 0.290 | 1.187 | 2.503 | 3.869 |
| 29054400 | D-glucitol (sorbitol) | 4.868 | 5.188 | 30.088 | 32.803 |
| 29071930 | Thymol | 0.558 | 0.488 | 4.342 | 3.244 |
| 29072200 | Hydroquinone | 0.709 | 1.118 | 4.538 | 6.264 |
| 29095010 | Guaiacol | 0.071 | 0.261 | 0.888 | 1.234 |
| 29124920 | Heliotropin (piperonyl aldehyde) | 0.000 | 0.000 | 0.000 | 0.000 |
| 29124940 | 3,4,5-trimethoxy-benzaldehyde | 0.251 | 0.000 | 1.091 | 0.943 |
| 29154010 | Monochloroacetic acide their salts and esters | 1.272 | 0.646 | 6.476 | 6.258 |
| 29163120 | Benzyl Benzoate | 0.624 | 0.192 | 2.678 | 1.772 |
| 29163150 | Benzocaine (ethylpara-amino benzoate) | 0.024 | 0.422 | 1.079 | 1.870 |
| 29163400 | Phenyl acetic acid | 0.110 | 0.016 | 0.590 | 0.662 |
| 29171940 | Ferrous fumerate | 0.850 | 0.547 | 3.974 | 3.832 |
| 29171970 | Ethoxy methylene malonate, diethyl malonate | 0.000 | 0.000 | 0.001 | 0.164 |
| 29181120 | Calcium lactate | 0.036 | 0.003 | 0.108 | 0.053 |
| 29181320 | Metroprolol tartrate | 1.002 | 0.979 | 5.021 | 5.039 |
| 29181510 | Potassium citrate | 0.126 | 0.134 | 1.590 | 1.382 |
| 29181520 | Sodium citrate | 0.705 | 0.785 | 4.899 | 6.415 |
| 29181550 | Ferric ammonium citrate | 0.061 | 0.203 | 0.323 | 0.656 |
| 29181610 | Calcium gluconate | 0.182 | 0.406 | 3.096 | 2.703 |
| 29181620 | Ferrous gluconate | 0.214 | 0.044 | 0.659 | 0.302 |
| 29182110 | Salicylic acid | 0.300 | 0.324 | 1.372 | 1.726 |
| 29182120 | Sodium salicylate | 0.192 | 0.158 | 1.502 | 1.010 |
| 29182200 | 0-acetylsalicylic acid its salts and estrs | 0.208 | 0.080 | 0.824 | 0.730 |
| 29182310 | Methyl salicylate | 0.499 | 0.632 | 3.882 | 4.227 |
| 29182320 | Amino salicylate | 0.052 | 0.124 | 0.297 | 0.346 |
| 29183030 | Nalidixic acid | 0.014 | 0.091 | 0.657 | 0.525 |
| 29199010 | Glycerophosphoric acid | 0.001 | 0.000 | 0.018 | 0.000 |
| 29199030 | Iron glycerophosphate | 0.021 | 0.000 | 0.037 | 0.006 |
| 29214600 | amfetamine INN and its related apis | 0.361 | 2.222 | 10.759 | 35.921 |
| 29215110 | o phenylanediamine | 0.102 | 0.000 | 0.477 | 0.582 |
| 29215120 | M-phenylenediamine (m-di aminobenzene) | 1.693 | 1.107 | 3.580 | 14.405 |
| 29215130 | P-phenylenediamine | 1.140 | 0.500 | 6.491 | 3.965 |
| 29215170 | Para amini acetanalide | 0.095 | 0.034 | 0.135 | 0.253 |
| 29223100 | Amfepra none(inn), methdone & mormethadonesalts | 0.048 | 0.216 | 0.159 | 0.629 |

| | | | | | |
|---|---|---|---|---|---|
| 29224100 | Lysine and its esters salts thereof | 0.128 | 0.539 | 0.844 | 1.751 |
| 29224210 | Glutamic acid | 0.056 | 0.052 | 0.116 | 0.168 |
| 29224220 | Monosodium glutamate (aginamoto) | 0.037 | 0.047 | 0.350 | 0.303 |
| 29224910 | Amino acetic acid (glycine) | 2.529 | 1.010 | 10.885 | 7.927 |
| 29224920 | N-methyl taurine | 0.002 | 0.000 | 0.017 | 0.034 |
| 29225013 | Procaine hydrochloride | 0.002 | 0.038 | 0.035 | 0.086 |
| 29225015 | L-tyrosine(p-hydroxyphenylamine) | 0.000 | 0.000 | 0.008 | 0.001 |
| 29225021 | Frusemide | 2.138 | 1.467 | 9.857 | 9.109 |
| 29225024 | D0mperid0ne | 0.455 | 0.452 | 4.298 | 3.654 |
| 29231000 | Choline and its salts | 1.455 | 0.532 | 5.355 | 3.853 |
| 29241100 | Meprobamate (inn) | 0.065 | 0.000 | 2.434 | 0.355 |
| 29242910 | Acetanilide | 0.000 | 0.015 | 0.123 | 0.080 |
| 29242960 | Pyrazinamide(pyrazine carboxamide) | 0.812 | 0.329 | 2.932 | 1.927 |
| 29242970 | Pretilachlor | 0.009 | 1.101 | 0.033 | 7.570 |
| 29242980 | Paracetamol | 0.000 | 6.620 | 37.308 | 40.560 |
| 29262000 | 1-Cyanoguanidine (dicyandiamide) | 0.000 | 0.094 | 0.002 | 0.099 |
| 29263000 | Fenproporex (inn) & its salts | 0.000 | 0.000 | 0.037 | 0.000 |
| 29264000 | Alpha-phenylacetoacetonitrile | 0.000 | 0.003 | 0.000 | 0.007 |
| 29280010 | Isoniazid | 0.100 | 0.025 | 0.548 | 0.532 |
| 29309014 | Industrial chemical | 0.000 | 0.559 | 0.000 | 3.002 |
| 29309040 | L-cystine (alpha-amino beta-thiopropionic acid) | 0.270 | 0.000 | 1.264 | 0.000 |
| 29322010 | Coumarin,mthylcoumrn & ehylcoumrn-lactones | 0.822 | 0.907 | 5.093 | 5.761 |
| 29331100 | Phenazone (antipyrin) and its derivatives | 0.793 | 0.659 | 5.318 | 4.808 |
| 29331910 | 3-carboxy (para sulpho-phenyl)-5-pyrazolone | 0.158 | 0.075 | 1.070 | 1.034 |
| 29331920 | 1 (2,5- dichloro-4-sulpho phenyl)-3-methyl 5 Pyrazolone | 0.096 | 0.071 | 0.485 | 0.464 |
| 29331930 | 3-methyl-1(4-sulpho-O-toluyl-5-pyrazolone) | 0.033 | 0.003 | 0.535 | 0.082 |
| 29331940 | Phenylmethylpyrazolone | 0.000 | 0.004 | 0.011 | 0.024 |
| 29331950 | 1-phenyl-5-pyrazolone-3-carboxylic acid | 0.000 | 0.000 | 0.019 | 0.000 |
| 29331960 | 1-(m-sulphophenyl)-3-pyrazolone | 0.000 | 0.000 | 0.000 | 0.059 |
| 29332910 | Tinidazole | 0.157 | 0.409 | 1.651 | 1.982 |
| 29332920 | Metronidazole metronidiazole benzoate | 1.648 | 1.335 | 7.705 | 8.906 |
| 29332930 | Mebendazole | 0.334 | 0.608 | 2.596 | 3.838 |
| 29332940 | Dimetridazole | 0.274 | 0.265 | 4.267 | 1.915 |
| 29334100 | Levorphanol (inn) and its salts | 0.394 | 0.000 | 0.815 | 0.000 |
| 29334110 | Levorphanol (inn) and its salts | 0.000 | 0.000 | 0.000 | 0.657 |
| 29334190 | Other Containing structure of quinoline or iso quinoline ring halogenated or non halogentated and not further fused | 0.000 | 0.000 | 0.000 | 2.734 |
| 29335200 | Malonylurea (barbituric acid) & its sals | 0.025 | 0.196 | 0.126 | 0.589 |

| | | | | | |
|---|---|---|---|---|---|
| 29335300 | Allobarbital and othr barbital compnds andits salts | 0.318 | 0.083 | 2.306 | 1.365 |
| 29335400 | Other derivatives of malonylurea (barbituric acid ), salts thereof | 0.157 | 0.044 | 0.913 | 0.450 |
| 29335910 | Aminophylline(cordophylin) | 0.100 | 0.015 | 0.404 | 0.160 |
| 29335920 | Trimethoprim | 1.137 | 0.729 | 6.402 | 6.681 |
| 29335930 | Diethyl carbanazine citrate | 0.005 | 0.141 | 0.150 | 0.183 |
| 29335940 | 1-Amino-4-Methyl piperazine | 0.160 | 0.489 | 1.781 | 2.827 |
| 29335950 | Bispiribac Sodium( Herbicide) | 0.147 | 1.501 | 0.147 | 5.240 |
| 29339100 | Alpra zolam, camazepam & other cmpnds of zepam, salts thereof | 2.297 | 0.969 | 10.256 | 9.852 |
| 29339200 | Azinphos-methyl (ISO) | 0.000 | 0.159 | 0.017 | 0.192 |
| 29349100 | Aminorex, brotizolam and other like cmpnds, salts thereof | 0.115 | 0.413 | 3.783 | 8.701 |
| 29349200 | Fentanyl | 0.000 | 0.000 | 0.061 | 0.543 |
| 29349910 | Chloro Thiophene-2-Carboxylic Acid | 0.000 | 0.000 | 0.044 | 0.038 |
| 29349990 | Other Hetrocyclic compounds | 60.540 | 61.977 | 273.275 | 365.936 |
| 29351000 | N-Methylperfluorooctane sulphonamide | 0.000 | 0.000 | 0.045 | 0.269 |
| 29352000 | N-Ethylperfluorooctane sulphonamide | 0.000 | 0.000 | 0.000 | 0.041 |
| 29355090 | Other Perfluro Octane Suphonomides | 0.285 | 0.153 | 0.932 | 0.901 |
| 29359011 | Sulphamethoxazole | 3.453 | 1.694 | 17.276 | 15.164 |
| 29359012 | Sulphafurazole | 0.000 | 0.002 | 0.006 | 0.002 |
| 29359013 | Sulphadiazine | 0.517 | 0.823 | 2.606 | 3.311 |
| 29359014 | Sulphadimidine | 0.013 | 0.000 | 0.048 | 0.018 |
| 29359015 | Sulphacetamide | 0.000 | 0.001 | 0.005 | 0.001 |
| 29359022 | Sulphamethiazole | 0.000 | 0.000 | 0.000 | 2.836 |
| 29359040 | Pyrazosuluron ethyl(Pesticide) | 0.000 | 3.802 | 0.000 | 3.885 |
| 29362100 | Vitamins a and their derivatives | 0.859 | 1.225 | 12.108 | 10.689 |
| 29362210 | Vitamin b1i(thiamine, aneurine) & its salt | 1.065 | 0.658 | 4.955 | 4.667 |
| 29362290 | Other vitamin b1i and its drivatives | 0.776 | 2.307 | 9.644 | 7.708 |
| 29362310 | Vitamin b2 (riboflavin, lactoplavin) and its salts | 0.587 | 1.450 | 5.561 | 6.329 |
| 29362390 | Other vitamin b2 and its derivatives | 0.000 | 0.083 | 0.131 | 0.085 |
| 29362400 | D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives | 0.073 | 0.034 | 0.375 | 0.186 |
| 29362500 | Vitamin b6 & its drvts | 0.014 | 0.085 | 0.079 | 0.557 |
| 29362610 | Vitamin b12 (cynocobalamin) | 0.066 | 0.278 | 0.414 | 0.918 |
| 29362690 | Other vitamin b12 and its derivatives | 0.256 | 0.291 | 1.707 | 6.294 |
| 29362700 | Vitamin c (ascorbic acid) & its drvtvs | 0.794 | 1.606 | 5.291 | 6.759 |
| 29362800 | Vitamin e and its derivatives | 1.648 | 2.461 | 9.925 | 12.432 |
| 29362910 | Folic acid (vitamin b9) | 0.786 | 0.548 | 3.099 | 3.205 |
| 29362920 | Nctnc acid & nctnmd(niacinamide/niacine | 7.356 | 5.790 | 43.021 | 38.398 |
| 29362930 | Vitamin k (menaphthonum b.p.) | 0.014 | 0.026 | 0.876 | 5.402 |
| 29362940 | Vitamin d | 2.847 | 2.460 | 9.240 | 14.791 |
| 29362950 | Vitamin h (bi0lin) | 0.034 | 0.007 | 0.344 | 0.137 |
| 29362990 | Other vitamins and thr drvtvs | 1.364 | 1.643 | 8.553 | 9.174 |

| | | | | | |
|---|---|---|---|---|---|
| 29369000 | Other, incl. natural concentrts | 4.353 | 5.501 | 19.375 | 28.789 |
| 29371100 | Somatotropin, its drvtvs& strctl analogves | 0.000 | 0.000 | 0.113 | 0.067 |
| 29371200 | Insulin and its salts | 5.977 | 6.524 | 23.508 | 22.238 |
| 29371900 | Other polypeptide hormones thr dtvtvs & strctl anlges | 3.795 | 5.635 | 14.532 | 20.272 |
| 29372100 | Cortisone,hydrocortisone,prednisone (dehy-drocortisone)and frednisolone and prdnsln(dehydrohydrocortisone) | 1.308 | 1.407 | 6.515 | 6.447 |
| 29372200 | Halgntd drvtvs of corti costeroidal | 4.534 | 3.803 | 18.709 | 16.025 |
| 29372300 | Oestrogens and progestogens | 3.169 | 3.663 | 12.812 | 11.428 |
| 29372900 | Othr steroidal hormons thr drvtvs and strctl anlges | 9.591 | 12.531 | 57.029 | 57.832 |
| 29375000 | Prostaglandins, tiromboxames& leukotrienesthr drvtvs & strclt anlges | 0.197 | 0.165 | 0.749 | 0.530 |
| 29379019 | Other Catecholamine hormones, their derivatives and structural analogues | 0.015 | 0.065 | 0.814 | 0.295 |
| 29379020 | Amino acide Derivatives | 2.779 | 0.530 | 11.000 | 7.847 |
| 29379090 | Other Amino acide Derivatives | 0.888 | 1.079 | 13.027 | 10.383 |
| 29381000 | Rutoside (rutin) and its derivatives | 0.000 | 0.000 | 0.002 | 0.001 |
| 29389010 | Digoxin | 0.047 | 0.357 | 1.118 | 0.753 |
| 29389090 | Other glycosides ntrl/rprdcd by synthsis &thr slts ethrs drvtvs | 2.962 | 6.977 | 22.665 | 37.043 |
| 29391100 | Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof | 0.012 | 0.000 | 0.016 | 0.132 |
| 29392010 | Quinine alkaloids | 0.000 | 0.000 | 0.000 | 0.000 |
| 29392020 | Quinine hydrochloride | 0.301 | 0.099 | 1.217 | 1.886 |
| 29392030 | Quinine sulphate | 0.077 | 0.045 | 0.621 | 0.243 |
| 29392040 | Chl0r0quine ph0sphate | 0.126 | 0.186 | 0.708 | 0.906 |
| 29393000 | Caffeine and its salts | 5.182 | 7.243 | 26.747 | 35.557 |
| 29394100 | Ephedrine & its salts | 0.181 | 0.072 | 1.086 | 1.364 |
| 29394400 | Norephedrine and its salts | 0.640 | 0.130 | 1.027 | 0.916 |
| 29394900 | Other ephedrives and thr salts | 0.221 | 0.269 | 1.188 | 1.039 |
| 29395900 | Other theophylline and aminophylline thr drvtvs, salts | 2.911 | 4.392 | 18.446 | 22.540 |
| 29396900 | Other alkaloids of rye ergot & drvtvs | 0.033 | 0.189 | 1.304 | 0.787 |
| 29397900 | Other of Vegitable origin | 9.518 | 10.595 | 57.878 | 81.499 |
| 29398000 | Non Vegetable Alkaloids | 0.329 | 0.775 | 7.202 | 5.828 |
| 29411010 | Penicillins and its salts | 0.000 | 0.013 | 0.015 | 0.084 |
| 29411020 | Ampicilline & its salts | 1.624 | 1.542 | 13.652 | 11.775 |
| 29411030 | Amoxycilline & its salts | 19.721 | 15.573 | 92.471 | 79.225 |
| 29411040 | Cloxacilline & its salts | 1.163 | 1.406 | 10.961 | 10.115 |
| 29411090 | Other penicillins & thr drvtvs wth a pentcillianic acid strctr slts thereof | 11.138 | 3.800 | 41.162 | 40.494 |
| 29412010 | Streptomycins | 0.000 | 0.000 | 0.006 | 0.032 |
| 29412090 | Other streptomycine & drvtvs, salts | 0.001 | 0.004 | 0.009 | 0.207 |
| 29413010 | Doxycylime & its salts | 0.003 | 0.018 | 0.376 | 0.422 |

| | | | | | |
|---|---|---|---|---|---|
| 29413020 | Tetracycline/oxytetra - cycline & hr salts | 0.179 | 0.105 | 1.482 | 0.484 |
| 29413090 | Other tetracyclines & thr drvtvs slts | 0.173 | 0.164 | 0.209 | 0.225 |
| 29414000 | Chloramphenicol & its drvtvs slts thereof | 0.095 | 0.044 | 1.225 | 1.011 |
| 29415000 | Erthromycin & its drvtvs slts thereof | 8.398 | 7.343 | 52.244 | 46.954 |
| 29419011 | Rifampicin | 0.372 | 0.762 | 4.816 | 7.478 |
| 29419014 | 1-Amino-4-Methyl piperazine (Rifaint) | 0.000 | 0.000 | 0.000 | 0.000 |
| 29419019 | Other rifampicin and its salts | 0.294 | 0.358 | 4.746 | 2.564 |
| 29419020 | Cephalexin & its salts | 1.071 | 0.593 | 6.590 | 3.111 |
| 29419030 | Ciprofloxacine & its salts | 1.790 | 2.668 | 9.906 | 11.356 |
| 29419040 | Gentamycin & its salts | 0.001 | 0.001 | 0.028 | 0.002 |
| 29419050 | Neomycin | 0.007 | 0.002 | 0.009 | 0.062 |
| 29419060 | Norfloxacin & its salts | 0.001 | 0.155 | 0.748 | 1.237 |
| 29419070 | Other antibiotics | 0.000 | 0.000 | 0.000 | 0.002 |
| 29419090 | Other antibiotics | 52.590 | 45.410 | 280.593 | 214.097 |
| 29420011 | Cefadroxil | 2.676 | 0.024 | 10.997 | 11.488 |
| 29420012 | Ibuprofane | 5.303 | 6.152 | 36.822 | 34.515 |
| 29420013 | Nifedipine | 0.244 | 0.102 | 0.939 | 1.489 |
| 29420014 | Ranitidine | 1.188 | 0.936 | 4.311 | 3.855 |
| 29420016 | Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptyline, Atenolol,Propanolol | 0.000 | 0.000 | 0.000 | 0.022 |
| 29420021 | Timolol maleate | 0.214 | 0.164 | 2.771 | 2.361 |
| 29420022 | Terbutoline sulphate | 0.221 | 0.050 | 0.632 | 0.601 |
| 29420024 | Imipramine hcl | 0.076 | 0.125 | 0.262 | 0.414 |
| 29420025 | Amitryptyline hcl | 0.497 | 0.740 | 2.877 | 2.616 |
| 29420027 | Atenolol, propronalol | 1.434 | 0.802 | 5.893 | 5.768 |
| 29420031 | Diloxanide furoate | 0.039 | 0.493 | 1.261 | 1.562 |
| 29420033 | Oxyclozanide | 0.576 | 0.973 | 3.042 | 4.396 |
| 29420034 | Famotidine | 1.179 | 1.304 | 6.458 | 7.029 |
| 29420090 | Other diloxanide furoate, cimetidine, famotidine nes | 98.239 | 95.198 | 524.650 | 537.506 |
| 90189097 | Surgical appliances | 0.014 | 0.012 | 0.080 | 0.116 |
| 29329300 | 3 -Carboxy(Para sulpho- phenyl)-5-Pyrazololne | 0.000 | 0.000 | 0.081 | 0.000 |
| 29329600 | Carbofuran | 0.000 | 0.000 | 0.001 | 0.000 |
| 29349930 | Pramoxine | 0.004 | 0.003 | 0.004 | 6.331 |
| 29355010 | Flubendiamide(insecticide) | 0.004 | 0.000 | 0.004 | 0.000 |
| 29373100 | Epinethrine | 0.000 | 0.000 | 0.000 | 0.000 |
| 29394500 | Levo Methaphatamine | 0.075 | 0.000 | 0.075 | 0.000 |
| 29396110 | Ergometrine | 0.000 | 0.000 | 0.000 | 0.000 |
| 29396190 | Other ergometrine salts | 0.004 | 0.000 | 0.004 | 0.000 |
| 29411050 | 6 - apa | 0.000 | 0.000 | 0.000 | 0.000 |
| 29419012 | 3 Formyl Rifa S V(Rifaint) | 0.000 | 0.000 | 0.000 | 0.000 |
| 29419013 | Rifa S or Rifa S Sodium (Rifaint) | 0.000 | 0.000 | 0.201 | 0.000 |
| 29420026 | Cysteanune hcl | 0.000 | 0.000 | 0.000 | 0.000 |
| 29420032 | Cimetidine | 0.001 | 0.003 | 0.001 | 0.035 |
| Grand Total | | 394.864 | 397.904 | 2138.673 | 2293.937 |

| Country-wise Imports of Bulk Drugs & Intermediates April-Sept 2025 $ mn | | |
|---|---|---|
| **Country** | **April - Sep 2024** | **April - Sep 2025** |
| Angola | 0.02 | 0.00 |
| Argentina | 3.02 | 0.17 |
| AUSTRALIA | 5.64 | 0.11 |
| Austria | 14.99 | 12.42 |
| Bangladesh | 0.01 | 0.35 |
| Belgium | 23.62 | 20.19 |
| Brazil | 1.23 | 1.15 |
| Bulgaria | 1.45 | 3.09 |
| Cambodia | 0.00 | 0.14 |
| Canada | 0.12 | 0.77 |
| Chile | 1.05 | 0.16 |
| CHINA | 1597.60 | 1533.86 |
| Colombia | 0.59 | 0.56 |
| Costa Rica | 0.05 | 0.00 |
| Croatia | 0.39 | 0.64 |
| Czech Rep. | 5.54 | 5.70 |
| Denmark | 11.41 | 18.63 |
| Egypt | 0.20 | 0.20 |
| Estonia | 0.47 | 0.00 |
| Finland | 0.16 | 0.78 |
| France | 20.46 | 16.10 |
| Germany | 36.23 | 60.07 |
| Greece | 1.07 | 1.23 |
| Guatemala | 0.02 | 0.00 |
| Honduras | 0.00 | 0.02 |
| Hong Kong | 10.51 | 10.61 |
| Hungary | 8.42 | 5.94 |
| Indonesia | 9.96 | 7.88 |
| Iran | 0.00 | 0.00 |
| Ireland | 0.73 | 0.51 |
| Israel | 2.74 | 5.80 |
| Italy | 62.45 | 56.42 |
| Japan | 16.61 | 10.85 |
| Jordan | 0.33 | 0.07 |
| Kenya | 0.05 | 0.00 |
| Korea Republic (South) | 11.10 | 8.01 |
| Kuwait | 0.00 | 0.00 |
| Latvia | 0.12 | 0.18 |
| Lebanon | 0.01 | 0.00 |
| Lithuania | 0.01 | 0.18 |
| Macao | 0.96 | 2.61 |
| Macedonia | 0.27 | 0.00 |
| Madagascar | 0.64 | 0.94 |
| Malaysia | 6.34 | 13.02 |
| Malta | 3.10 | 3.01 |

| | | |
|---|---|---|
| Mexico | 13.50 | 22.64 |
| Morocco | 0.12 | 0.20 |
| Nepal | 0.01 | 0.00 |
| Netherlands | 34.29 | 27.18 |
| New Zealand | 0.00 | 0.00 |
| Nigeria | 0.00 | 0.17 |
| Norway | 0.00 | 0.00 |
| Pakistan | 0.01 | 0.01 |
| Paraguay | 0.02 | 0.00 |
| Peru | 0.09 | 0.00 |
| POLAND | 0.82 | 0.65 |
| Portugal | 1.71 | 2.72 |
| Puerto Rico | 0.00 | 0.00 |
| Qatar | 0.00 | 0.08 |
| Romania | 1.66 | 1.27 |
| Russia | 0.53 | 0.15 |
| Saudi Arabia | 0.04 | 0.02 |
| Seychelles | 0.12 | 0.00 |
| Singapore | 13.25 | 11.18 |
| Slovak Rep | 1.05 | 0.73 |
| Slovenia | 17.50 | 23.61 |
| South Africa | 0.04 | 0.00 |
| Spain | 40.20 | 42.71 |
| Sri Lanka | 0.00 | 0.32 |
| Swaziland | 0.00 | 0.00 |
| SWEDEN | 0.51 | 0.22 |
| Switzerland | 25.25 | 40.05 |
| Taiwan | 16.51 | 16.44 |
| Thailand | 3.03 | 4.39 |
| Turkey | 0.54 | 0.12 |
| Ukraine | 0.02 | 0.52 |
| United Arab Emirates | 10.68 | 3.75 |
| United Kingdom | 16.01 | 19.69 |
| UNSPECIFIED | 0.56 | 0.49 |
| Uruguay | 0.00 | 0.02 |
| Uzbekistan | 0.00 | 0.03 |
| Vietnam Soc Rep | 4.19 | 6.61 |
| U S A | 47.48 | 35.17 |
| | 2109.44 | 2063.53 |

# HS Code-wise Imports of Bulk Drugs & Intermediates
# April-Sep 2025

| | | | | Value in Mn $ | |
|---|---|---|---|---|---|
| **HS codes** | **Description** | **Sep 2024** | **Sep 2025** | **2024-25** | **2025-26** |
| 17023010 | Glucose liquid | 0.000 | 0.009 | 0.034 | 0.089 |
| 17023020 | Glucose solid | 0.030 | 0.022 | 0.441 | 0.487 |
| 17023031 | Dextrose,solid | 0.033 | 0.045 | 0.255 | 0.398 |
| 17023039 | Dextrose other than solid | 0.146 | 0.078 | 0.486 | 0.541 |
| 17024039 | Dextrose other than solid | 0.000 | 0.001 | 0.000 | 0.132 |
| 29051410 | Ethambutol, ethambutol hcl | 0.106 | 0.073 | 1.865 | 2.126 |
| 29051420 | Salbutamol sulphate | 0.024 | 0.031 | 0.154 | 0.206 |
| 29054300 | Mannitol | 5.006 | 4.416 | 24.762 | 29.991 |
| 29054400 | D-glucitol (sorbitol) | 1.248 | 0.951 | 5.689 | 5.449 |
| 29071930 | Thymol | 0.008 | 0.014 | 0.053 | 0.063 |
| 29072200 | Hydroquinone | 1.887 | 3.207 | 16.445 | 18.081 |
| 29095010 | Guaiacol | 0.259 | 0.442 | 0.550 | 1.539 |
| 29124940 | 3,4,5-trimethoxy-benzaldehyde | 0.094 | 0.000 | 0.271 | 0.290 |
| 29154010 | Monochloroacetic acide their salts and esters | 0.142 | 0.449 | 1.377 | 0.794 |
| 29163120 | Benzyl Benzoate | 0.108 | 0.069 | 0.264 | 0.567 |
| 29163150 | Benzocaine (ethylpara-amino benzoate) | 0.000 | 0.010 | 0.001 | 0.055 |
| 29163400 | Phenyl acetic acid | 0.848 | 1.496 | 2.572 | 1.496 |
| 29171940 | Ferrous fumerate | 0.000 | 0.000 | 0.027 | 0.040 |
| 29171970 | Ethoxy methylene malonate, diethyl malonate | 1.637 | 0.621 | 10.366 | 7.397 |
| 29181120 | Calcium lactate | 0.056 | 0.022 | 0.248 | 0.184 |
| 29181320 | Metroprolol tartrate | 0.000 | 0.217 | 0.214 | 1.322 |
| 29181510 | Potassium citrate | 0.107 | 0.004 | 1.016 | 0.595 |
| 29181520 | Sodium citrate | 0.079 | 0.276 | 1.015 | 2.066 |
| 29181610 | Calcium gluconate | 0.750 | 0.401 | 4.666 | 3.857 |
| 29181620 | Ferrous gluconate | 0.000 | 0.008 | 0.000 | 0.023 |
| 29182110 | Salicylic acid | 1.945 | 1.469 | 14.222 | 10.357 |
| 29182120 | Sodium salicylate | 0.000 | 0.002 | 0.032 | 0.064 |
| 29182200 | 0-acetylsalicylic acid its salts and estrs | 0.072 | 0.000 | 0.207 | 0.371 |
| 29182310 | Methyl salicylate | 0.065 | 0.066 | 0.606 | 0.497 |
| 29182320 | Amino salicylate | 0.000 | 0.000 | 0.000 | 0.000 |
| 29183030 | Nalidixic acid | 0.000 | 0.077 | 0.560 | 0.320 |
| 29199010 | Glycerophosphoric acid | 0.000 | 0.000 | 0.002 | 0.000 |
| 29214600 | amfetamine INN and its related apis | 0.003 | 0.055 | 0.238 | 0.139 |
| 29215110 | o phenylanediamine | 1.486 | 0.935 | 9.302 | 7.087 |
| 29215120 | M-phenylenediamine (m-di aminobenzene) | 0.381 | 0.319 | 2.000 | 1.946 |
| 29215130 | P-phenylenediamine | 0.164 | 0.544 | 2.794 | 2.583 |
| 29224100 | Lysine and its esters salts thereof | 7.523 | 9.195 | 65.173 | 57.257 |
| 29224210 | Glutamic acid | 0.000 | 0.000 | 0.010 | 0.031 |
| 29224220 | Monosodium glutamate (aginamoto) | 6.157 | 4.574 | 33.622 | 30.692 |

| | | | | | |
|---|---|---|---|---|---|
| 29224910 | Amino acetic acid (glycine) | 2.387 | 1.441 | 12.610 | 8.969 |
| 29224920 | N-methyl taurine | 0.366 | 0.533 | 0.670 | 2.424 |
| 29331940 | Phenylmethylpyrazolone | 0.000 | 0.000 | 0.000 | 0.006 |
| 29331950 | 1-phenyl-5-pyrazolone-3-carboxylic acid | 0.000 | 0.000 | 0.000 | 0.286 |
| 29331960 | 1-(m-sulphophenyl)-3-pyrazolone | 0.000 | 0.000 | 0.107 | 0.338 |
| 29331970 | Analgin | 0.523 | 0.158 | 1.812 | 1.180 |
| 29331980 | 0xyphenbutazone | 0.000 | 0.000 | 0.013 | 0.151 |
| 29332910 | Tinidazole | 0.026 | 0.093 | 0.046 | 0.226 |
| 29332920 | Metronidazole metronidiazole benzoate | 0.918 | 0.061 | 6.064 | 4.672 |
| 29332930 | Mebendazole | 0.000 | 0.000 | 0.118 | 0.002 |
| 29332940 | Dimetridazole | 0.072 | 0.000 | 0.116 | 0.000 |
| 29334190 | Other Containing structure of quinoline or iso quinoline ring halogenated or non halogentated and not further fused | 0.000 | 0.029 | 0.000 | 0.029 |
| 29335200 | Malonylurea (barbituric acid) & its sals | 0.591 | 0.386 | 2.730 | 3.211 |
| 29335300 | Allobarbital and othr barbital compnds andits salts | 0.001 | 0.000 | 0.004 | 0.037 |
| 29335400 | Other derivatives of malonylurea (barbituric acid ), salts thereof | 0.000 | 0.199 | 0.003 | 0.625 |
| 29335500 | Loprazolam, mecloqualone, methaqualone , ziperol, salts thereof | 0.000 | 0.000 | 0.000 | 0.000 |
| 29335910 | Aminophylline(cordophylin) | 0.000 | 0.000 | 0.367 | 0.107 |
| 29335920 | Trimethoprim | 0.025 | 0.018 | 0.094 | 0.216 |
| 29335940 | 1-Amino-4-Methyl piperazine | 0.000 | 0.000 | 0.012 | 0.019 |
| 29335950 | Bispiribac Sodium( Herbicide) | 0.000 | 0.000 | 0.000 | 0.010 |
| 29339100 | Alpra zolam, camazepam & other cmpnds of zepam, salts thereof | 0.017 | 0.008 | 1.155 | 0.985 |
| 29339200 | Azinphos-methyl (ISO) | 0.000 | 0.000 | 0.000 | 0.000 |
| 29349100 | Aminorex, brotizolam and other like cmpnds, salts thereof | 0.000 | 0.000 | 0.023 | 0.000 |
| 29349200 | Fentanyl | 0.085 | 0.077 | 0.444 | 0.260 |
| 29349910 | Chloro Thiophene-2-Carboxylic Acid | 0.034 | 0.069 | 0.111 | 0.460 |
| 29349930 | Pramoxine | 0.000 | 0.000 | 0.002 | 0.002 |
| 29349990 | Other Hetrocyclic compounds | 45.896 | 55.033 | 360.073 | 324.310 |
| 29351000 | N-Methylperfluorooctane sulphonamide | 0.000 | 0.000 | 0.022 | 0.000 |
| 29355090 | Other Perfluro Octane Suphonomides | 0.006 | 0.018 | 0.015 | 0.786 |
| 29359011 | Sulphamethoxazole | 0.000 | 0.000 | 0.025 | 0.018 |
| 29359013 | Sulphadiazine | 0.074 | 0.054 | 0.324 | 0.490 |
| 29359014 | Sulphadimidine | 0.176 | 0.000 | 1.011 | 0.979 |
| 29359023 | Sulphamoxole | 0.000 | 0.000 | 0.000 | 0.000 |
| 29359040 | Pyrazosuluron ethyl(Pesticide) | 0.000 | 0.000 | 0.000 | 0.404 |
| 29362100 | Vitamins a and their derivatives | 0.801 | 2.724 | 6.611 | 8.804 |

| | | | | | |
|---|---|---|---|---|---|
| 29362210 | Vitamin b1i(thiamine, aneurine) & its salt | 2.308 | 1.228 | 7.295 | 12.679 |
| 29362290 | Other vitamin b1i and its drivatives | 0.118 | 0.109 | 1.642 | 1.431 |
| 29362310 | Vitamin b2 (riboflavin, lactoplavin) and its salts | 1.151 | 0.778 | 6.951 | 4.296 |
| 29362390 | Other vitamin b2 and its derivatives | 0.343 | 0.002 | 3.105 | 1.752 |
| 29362400 | D-or dl-pantothenic acid (vitamin b3 or vitamin b5) and its derivatives | 0.595 | 0.799 | 4.525 | 4.688 |
| 29362500 | Vitamin b6 & its drvts | 0.863 | 0.573 | 6.933 | 6.460 |
| 29362610 | Vitamin b12 (cynocobalamin) | 1.579 | 2.563 | 13.069 | 17.520 |
| 29362690 | Other vitamin b12 and its derivatives | 0.086 | 0.621 | 0.754 | 2.220 |
| 29362700 | Vitamin c (ascorbic acid) & its drvtvs | 1.832 | 1.434 | 7.619 | 14.206 |
| 29362800 | Vitamin e and its derivatives | 3.339 | 3.553 | 22.328 | 30.232 |
| 29362910 | Folic acid (vitamin b9) | 0.034 | 0.498 | 1.439 | 3.297 |
| 29362920 | Nctnc acid & nctnmd(niacinamide/niacine | 0.397 | 0.168 | 1.037 | 0.496 |
| 29362930 | Vitamin k (menaphthonum b.p.) | 0.362 | 0.288 | 1.254 | 1.149 |
| 29362940 | Vitamin d | 0.299 | 1.014 | 5.934 | 7.953 |
| 29362950 | Vitamin h (bi0lin) | 0.059 | 0.190 | 0.650 | 0.877 |
| 29362990 | Other vitamins and thr drvtvs | 1.847 | 1.712 | 10.179 | 6.577 |
| 29369000 | Other, incl. natural concentrts | 0.077 | 0.104 | 0.491 | 1.171 |
| 29371100 | Somatotropin, its drvtvs& strctl analogves | 0.000 | 0.002 | 0.000 | 0.003 |
| 29371200 | Insulin and its salts | 1.518 | 6.378 | 17.489 | 29.827 |
| 29371900 | Other polypeptide hormones thr dtvtvs & strctl anlges | 0.926 | 3.437 | 19.203 | 35.645 |
| 29372100 | Cortisone,hydrocortisone,prednisone (dehy-drocortisone)and frednisolone and prdnsln(dehydrohydrocortisone) | 2.016 | 2.177 | 22.644 | 18.209 |
| 29372200 | Halgntd drvtvs of corti costeroidal | 2.718 | 2.427 | 12.735 | 14.215 |
| 29372300 | Oestrogens and progestogens | 3.457 | 1.981 | 29.159 | 27.590 |
| 29372900 | Othr steroidal hormons thr drvtvs and strctl anlges | 7.861 | 9.460 | 52.947 | 52.292 |
| 29373100 | Epinethrine | 0.000 | 0.000 | 0.000 | 0.001 |
| 29375000 | Prostaglandins, tiromboxames& leukotrienesthr drvtvs & strclt anlges | 0.555 | 0.110 | 3.577 | 1.002 |
| 29379011 | Epinethrine | 0.000 | 0.000 | 0.001 | 0.003 |
| 29379019 | Other Catecholamine hormones, their derivatives and structural analogues | 0.547 | 0.695 | 3.012 | 2.100 |
| 29379020 | Amino acide Derivatives | 0.556 | 0.937 | 6.075 | 4.563 |
| 29379090 | Other Amino acide Derivatives | 5.019 | 5.514 | 29.904 | 33.033 |
| 29381000 | Rutoside (rutin) and its derivatives | 0.675 | 0.516 | 3.163 | 2.961 |
| 29389010 | Digoxin | 0.000 | 0.112 | 0.023 | 0.112 |
| 29389020 | Digitalis glycosides | 0.000 | 0.000 | 0.086 | 0.000 |
| 29389090 | Other glycosides ntrl/rprdcd by synthsis &thr slts ethrs drvtvs | 3.868 | 5.836 | 36.972 | 32.690 |

| | | | | | |
|---|---|---|---|---|---|
| 29391100 | Concentrates of poppy straw cmpnds of morphin, codeine, codone, the baine, salts thereof | 3.862 | 0.013 | 9.393 | 1.485 |
| 29392010 | Quinine alkaloids | 0.037 | 0.066 | 0.355 | 0.452 |
| 29392020 | Quinine hydrochloride | 0.000 | 0.000 | 0.004 | 0.000 |
| 29392030 | Quinine sulphate | 0.119 | 0.000 | 0.247 | 0.198 |
| 29393000 | Caffeine and its salts | 2.269 | 2.148 | 11.016 | 18.279 |
| 29394100 | Ephedrine & its salts | 0.000 | 0.000 | 0.006 | 0.089 |
| 29394300 | Cathine(INN) & its salts | 0.000 | 0.000 | 0.000 | 0.002 |
| 29394400 | Norephedrine and its salts | 0.000 | 0.000 | 0.001 | 0.015 |
| 29394500 | Levo Methaphatamine | 0.000 | 0.000 | 0.001 | 0.000 |
| 29394900 | Other ephedrives and thr salts | 0.000 | 0.133 | 0.387 | 0.526 |
| 29395900 | Other theophylline and aminophylline thr drvtvs, salts | 0.294 | 0.182 | 1.510 | 2.920 |
| 29396190 | Other ergometrine salts | 0.000 | 0.000 | 0.096 | 0.025 |
| 29396210 | Ergotamine tartarate | 0.000 | 0.000 | 0.364 | 0.000 |
| 29396290 | Other ergotamine salts | 0.000 | 0.000 | 0.036 | 0.000 |
| 29396900 | Other alkaloids of rye ergot & drvtvs | 0.705 | 0.422 | 1.999 | 1.315 |
| 29397200 | Cocaine, ecgonine, levometamfetamin, metamfetamine (INN), metamfetamine racemate; salts, esters and other derivatives thereof | 0.000 | 0.001 | 0.090 | 0.001 |
| 29397900 | Other of Vegitable origin | 0.084 | 0.179 | 1.494 | 4.880 |
| 29398000 | Non Vegetable Alkaloids | 0.415 | 0.245 | 6.170 | 1.517 |
| 29411010 | Penicillins and its salts | 13.606 | 18.255 | 96.725 | 60.034 |
| 29411020 | Ampicilline & its salts | 0.023 | 0.022 | 0.302 | 0.042 |
| 29411030 | Amoxycilline & its salts | 4.165 | 3.809 | 24.892 | 19.061 |
| 29411040 | Cloxacilline & its salts | 0.000 | 0.000 | 0.402 | 0.394 |
| 29411050 | 6 - apa | 39.769 | 18.872 | 217.508 | 173.529 |
| 29411090 | Other penicillins & thr drvtvs wth a pentcillianic acid strctr slts thereof | 4.605 | 9.088 | 42.325 | 44.767 |
| 29412010 | Streptomycins | 0.498 | 0.295 | 2.374 | 2.485 |
| 29412090 | Other streptomycine & drvtvs, salts | 0.323 | 0.047 | 1.254 | 0.872 |
| 29413010 | Doxycylime & its salts | 1.187 | 1.530 | 9.214 | 13.727 |
| 29413020 | Tetracycline/oxytetra - cycline & hr salts | 0.725 | 0.747 | 5.352 | 5.737 |
| 29413090 | Other tetracyclines & thr drvtvs slts | 1.236 | 1.292 | 10.831 | 11.531 |
| 29414000 | Chloramphenicol & its drvtvs slts thereof | 0.407 | 0.056 | 1.434 | 0.226 |
| 29415000 | Erthromycin & its drvtvs slts thereof | 11.503 | 14.912 | 81.377 | 94.886 |
| 29419011 | Rifampicin | 3.695 | 2.738 | 18.352 | 32.881 |
| 29419013 | Rifa S or Rifa S Sodium (Rifaint) | 0.863 | 1.704 | 5.699 | 18.725 |
| 29419014 | 1-Amino-4-Methyl piperazine (Rifaint) | 0.000 | 0.000 | 0.076 | 0.000 |
| 29419019 | Other rifampicin and its salts | 3.070 | 5.399 | 26.573 | 31.156 |
| 29419020 | Cephalexin & its salts | 4.853 | 2.336 | 19.093 | 14.236 |
| 29419030 | Ciprofloxacine & its salts | 0.905 | 0.870 | 5.477 | 3.076 |
| 29419040 | Gentamycin & its salts | 0.220 | 0.688 | 4.230 | 3.123 |
| 29419050 | Neomycin | 0.479 | 0.495 | 1.559 | 1.917 |

| | | | | | |
|---|---|---|---|---|---|
| 29419060 | Norfloxacin & its salts | 1.608 | 0.000 | 6.971 | 2.657 |
| 29419090 | Other antibiotics | 59.150 | 64.436 | 377.243 | 389.763 |
| 29420011 | Cefadroxil | 0.422 | 0.559 | 1.395 | 0.622 |
| 29420012 | Ibuprofane | 0.020 | 0.713 | 1.626 | 4.514 |
| 29420013 | Nifedipine | 0.000 | 0.000 | 0.010 | 0.000 |
| 29420014 | Ranitidine | 0.000 | 0.000 | 0.000 | 0.189 |
| 29420015 | Danes salt of D(-) phenyl glycine | 0.846 | 1.350 | 9.138 | 8.760 |
| 29420016 | Timolo maleate, terbutoline sulphate, imipramine HCl, amitryptyline, Atenolol,Propanolol | 1.459 | 1.631 | 13.390 | 7.148 |
| 29420021 | Timolol maleate | 0.000 | 0.000 | 0.155 | 0.136 |
| 29420022 | Terbutoline sulphate | 0.000 | 0.000 | 0.000 | 0.023 |
| 29420023 | D(-) phenyl glycin chloride HCL (DPGCH) | 0.000 | 0.000 | 0.000 | 0.037 |
| 29420025 | Amitryptyline hcl | 0.000 | 0.000 | 0.029 | 0.000 |
| 29420026 | Cysteanune hcl | 0.124 | 0.293 | 1.324 | 1.845 |
| 29420027 | Atenolol, propronalol | 0.000 | 0.000 | 1.017 | 0.035 |
| 29420032 | Cimetidine | 0.074 | 0.003 | 0.337 | 0.189 |
| 29420034 | Famotidine | 0.000 | 0.049 | 0.182 | 0.227 |
| 29420090 | Other diloxanide furoate, cimetidine, famotidine nes | 26.877 | 23.599 | 157.981 | 162.327 |
| 90189097 | Surgical appliances | 0.027 | 0.392 | 2.111 | 0.570 |
| Grand Total | | 317.893 | 325.780 | 2109.440 | 2063.532 |

# BDMAI IS PARTICIPATING IN

CPHI India | PMEC India

**India Expo Centre, Greater Noida, Delhi NCR**

**Please visit Stall No. 2A.13**
**Hall No. 2 A**
**25-27th November 2025**




## Important Note:

The organizers of Global ChemiShow offered 30 stalls (fully furnished 12 sq. meter stalls) on Complimentary basis. 16 of our members have already taken the Stalls. Members who are interested to avail these FREE stalls, please write to ed@bdmai.org ; info@bdmai.org; Stalls will be allotted on first-come-first-serve basis.

The organizers have also provided a separate Lounge for Procurement Personnel. Exhibitors will visit this Lounge and interact with the procurement persons available. Interested Procurement Executives may register by visiting their website www.globalchemshow.com

TRST01

TRUST · TRANSPARENCY · TRACEABILITY

# Sustainability Consulting & ESG Reporting for Pharmaceutical Industry

## Consulting Support

- **End-to-end ESG report** preparation and sustainability compliance support
- Support for building **supplier-specific** sustainability reports
- **In-house assistance** for data collection and report preparation
- **GHG (Scope 1 & 2)** calculations as per IPCC/GHG Protocol standards
- **Internal validation and audit coordination** to ensure accuracy and readiness
- **Sustainability reports** with GRI tagging and management presentations
- **Gap analysis report preparation** for key improvements and adoption of best practices

## Footprint ESG Reporting Tool

- Manage **subsidiaries, plants, and SBUs** in one platform
- **Single data entry** mapped to global ESG frameworks (GRI, BRSR, SASB, etc.)
- **Role-based access** for Environment, HR, CSR, and Operations teams
- **Automated GHG calculators** with analytics dashboards
- **Excel upload & API integration** with ERP systems
- **Custom dashboards** and **on-site/online training** for users

## Management Team

**Prabir Mishra**
Founder & CEO
IIM (A)
Investment Banker

**Manoj Vembu**
Founder & COO
CA & HBS
Technology, Fund Mgmt & Business management

**Dr. Susanta Kumar Barik**
Director
Phd, IIFM
Agri Sustainability & Traceability and Government Projects

## Consulting Support

**Shiva Shankar Gaud**
Head of Sustainability
shiv.s@trst01.com
+91 9666543007

**Anuj Kumar Sahu**
Manager ESG
anuj.s@trst01.com
+91 7841029181

+65 8809 8140 +91 91001 06371

Trayambhu Tech Solutions Private Limited (TRST01)
4A101B, WeWork Krishe Emerald, Whitefields,
Hyderabad 500081.